Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell TypeRecurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Interventions
- Procedure: Autologous Bone Marrow TransplantationProcedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarmustineDrug: CyclophosphamideDrug: CytarabineDrug: EtoposideDrug: IbrutinibOther: Laboratory Biomarker AnalysisDrug: MelphalanOther: Placebo AdministrationOther: Pharmacogenomic Study
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 92
- Registration Number
- NCT02443077
- Locations
- 🇺🇸
Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States
🇺🇸Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States
🇺🇸Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho, United States
AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 22
- Registration Number
- NCT02440568
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia
- Interventions
- Drug: BusulfanDrug: FludarabineDrug: ClofarabineBiological: Stem Cell InfusionRadiation: Total Body Irradiation (TBI)Drug: ThymoglobulinDrug: DecitabineDrug: CytarabineDrug: CyclophosphamideDrug: IdarubicinDrug: TacrolimusDrug: Mycophenolate mofetil
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT02441803
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT02433483
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Jianxiang Wang
- Target Recruit Count
- 300
- Registration Number
- NCT02432872
- Locations
- 🇨🇳
Treatment and Diagnosis Center of Leukemia, Tianjin, Tianjin, China
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Mantle Cell LymphomaPleomorphic Variant Mantle Cell LymphomaBlastoid Variant Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 131
- Registration Number
- NCT02427620
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
- Conditions
- Recurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic LeukemiaRecurrent Ph-Like Acute Lymphoblastic LeukemiaRefractory Ph-Like Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT02420717
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
- Conditions
- Acute Lymphoid LeukemiaAcute Myeloid LeukemiaMixed Lineage Acute Leukemia
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02419755
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Precursor-B Acute Lymphoblastic LeukemiaLymphoblastic LymphomaLymphomaLeukemia
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2018-06-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT02419469
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT02416908
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.